IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax

IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF. The dosing has been completed successfully and doses up to 7.5 mg/kg have been administered, as per protocol.

Inhalation anthrax is a potentially deadly infectious disease with limited treatment options, in particular for the advanced stage of infection after the initial appearance of symptoms. IQNLF is a fully human antibody developed by IQ Therapeutics, as part of a dual antibody treatment of inhalation anthrax. IQNLF is formulated in combination with a second fully human antibody (IQNPA) forming IQ-DAA. Pre-clinical experiments have indicated high efficacy of IQ-DAA, even in advanced stage of disease. Survival rates of 100% could be obtained in post-exposure treatment rabbit studies, even when administered 48 hours post-exposure, well into the symptomatic stage of the disease.

"The outcome of the clinical study will provide more insight in the safety of IQNLF and how well the antibody is accepted by the human body at levels that are projected to be efficacious" says Dr. Roland Lageveen, CEO of IQ Therapeutics. "It represents another important milestone in the development of IQ-DAA, and the initial results reflect the value of IQ's Cloning the Human Response technology."

IQNLF and IQNPA have been developed using the Cloning the Human Response(TM) technology, a proprietary technology of IQ Therapeutics, generating fully human antibodies from immunized donors. The technology results in antibodies which have been matured and optimized by the human immune system and are therefore most suitable for fighting infectious diseases in humans.